Equity Details
Price & Market Data
Price: $37.35
Daily Change: -$2.73 / 7.30%
Daily Range: $35.87 - $40.60
Market Cap: $1,760,156,800
Daily Volume: 1,052,653
Performance Metrics
1 Week: 24.93%
1 Month: 12.71%
3 Months: -1.86%
6 Months: 44.62%
1 Year: 232.0%
YTD: 17.25%
About MBX Biosciences, Inc. (MBX)
Comprehensive data for MBX Biosciences, Inc. (MBX). Price: 37.35, daily change: -$2.73 / 7.30%. Market cap: 1,760,156,800. Performance over 3-month, 6-month, and 52-week periods.
Company Details
Employees: 63
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.